OvarianCancer,BRCA,PARPinhibitor

Mashup Score: 11

Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study - 12 hour(s) ago

AbstractBackground. Patients with a germline BRCA pathogenic variant (gBRCA-PV) and advanced high grade ovarian carcinoma (aHGOC) experience higher hematol

Source: academic.oup.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncJournal
  
  Patients with #OvarianCancer and a germline #BRCA pathogenic variant (gBRCA-PV) do not experience higher hematological AEs vs. non-gBRCA-PV carriers while on #PARPinhibitor therapy. @curijoey @ValenzaCarmine @darioT_ https://t.co/BJBJgrHvYE https://t.co/E6HHfnOQ8M